

Data-driven Subgroups Of Patients With Type 1 Diabetes Based On Health Technology For Insulin Delivery



F.J. Somolinos-Simón¹, G. García-Sáez^{1,2}, J. Tapia-Galisteo^{1,2}, M.E. Hernando^{1,2}

¹Center for Biomedical Technology, ETSI de Telecomunicación, Universidad Politécnica de Madrid, Madrid, Spain ² CIBER-BBN: Networking Research Centre for Bioengineering, Biomaterials and Nanomedicine, Madrid, Spain

Introduction

Type 1 Diabetes (T1D) and its complications are a major cause of morbidity and mortality in the world.

Patients with T1D require the administration of insulin to maintain glycemic control.

Currently, two modes of subcutaneous insulin delivery have gained wider acceptance:

- Multiple daily injections (MDI).
- Continuous subcutaneous insulin infusion (CSII).


Randomized controlled trials (RCT) have shown that, when compared with MDI, CSII was associated with a slightly lower glycated hemoglobin (HbA1c) level.

Aims


The case study on diabetes of the H2020 HTx project (htxh2020.eu) aims to link evidence from RCTs to Real World Data and estimate the impact of health technology on specific subgroups of patients, as a first step to build prediction models to personalize treatment strategies. This work aims:

- To assess if patients with T1D can be stratified in subgroups according to different determinants.
- To analyze if subgroups are associated to treatment strategies.

Methods




Use of a longitudinal, prospective data repository with T1D patients from 83 clinics in the United Stetes (T1D Exchange).



Preprocessing and filtering of data in order to obtain adult individuals with more than five years of disease duration from initial enrollment (n = 8034).




A data-driven TwoStep clustering analysis based on age at diagnosis, diabetes duration, body mass index (bmi) or HbA1c.



The optimal number of clusters (five) was estimated on the basis of silhouette width.

Results



CLUSTER	AGE AT DIAGNOSIS (YEARS)		DIABETES DURATION (YEARS)		HBA1C (%)		BMI (KG/M²)	
	Mean	SD	Mean	SD	Mean	SD	Mean	SD
1	14.69	8.22	38.90	7.32	7.34	0.95	26.17	3.49
2	14.58	9.19	21.85	10.01	7.94	1.02	34.36	3.14
3	9.26	5.18	13.54	5.85	10.12	1.08	25.07	3.72
4	34.68	8.77	16.32	7.03	7.62	1.13	26.24	3.65
5	9.72	4.84	15.01	6.12	7.39	0.77	24.62	2.69

*SD: standard deviation

Conclusions

This preliminary work shows that **T1D** patients can be stratified in subgroups.

Future research includes study of complications and drugs associated to different clusters and additional data sources and creation a powerful tool to account for treatment effectiveness in patients subgroups.



© This project has received funding from European Union's Horizon 2020 research and innovation programme under grant agreement № 825162.



Francisco Javier Somolinos Simón (javier.ssimon@upm.es)

